| Name | Albiglutide |
|---|---|
| Synonyms |
Gsk 716155
7-36-Glucagon-like peptide I (8-glycine) (human), fusion protein with 7-36-glucagon-like peptide I (8-glycine) (human) fusion protein with serum Albugon Naliglutide Unii-5E7U48495e 7-36-Glucagon-likepeptide I [8-glycine] (huMan), fusion protein with 7-36-glucagon-like peptide I[8-glycine] (huMan) fusion protein with seruM albuMin (huMan) L-Histidylglycyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L
 -lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-argininamide |
| Description | Albiglutide, a glucagon-like peptide-1 (GLP-1) mimetic, is a long-acting GLP-1 receptor agonist. Albiglutide significantly reduces glycosylated hemoglobin (A1C). Albiglutide can be used for type 2 diabetes (T2D) research. Albiglutide is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin[1][2][3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C148H224N40O45 |
| Molecular Weight | 3283.603 |
| Exact Mass | 3281.646973 |
| LogP | -5.20 |
| Index of Refraction | 1.661 |
| Storage condition | -20℃ |